Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Robert Allen III sold 18,189 shares of the company's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $1.54, for a total transaction of $28,011.06. Following the completion of the transaction, the insider owned 133,879 shares in the company, valued at approximately $206,173.66. This represents a 11.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Invivyd Stock Up 6.5%
Shares of NASDAQ:IVVD opened at $1.65 on Thursday. The firm has a fifty day moving average of $2.19 and a two-hundred day moving average of $1.75. Invivyd, Inc. has a 12-month low of $0.46 and a 12-month high of $3.07. The firm has a market capitalization of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on IVVD. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Invivyd in a research report on Monday, December 29th. Zacks Research raised shares of Invivyd from a "strong sell" rating to a "hold" rating in a research report on Thursday, November 13th. HC Wainwright lifted their target price on shares of Invivyd from $5.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, October 31st. D. Boral Capital reissued a "hold" rating on shares of Invivyd in a research report on Tuesday, November 25th. Finally, BTIG Research restated a "buy" rating on shares of Invivyd in a report on Wednesday, January 21st. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.00.
Check Out Our Latest Research Report on Invivyd
Hedge Funds Weigh In On Invivyd
A number of institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC acquired a new stake in shares of Invivyd in the fourth quarter worth $53,809,000. BVF Inc. IL bought a new position in Invivyd in the 4th quarter worth $48,227,000. RA Capital Management L.P. acquired a new position in Invivyd during the 3rd quarter worth $18,831,000. ADAR1 Capital Management LLC bought a new stake in Invivyd during the third quarter valued at about $8,108,000. Finally, Janus Henderson Group PLC boosted its holdings in Invivyd by 28.2% during the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company's stock valued at $80,870,000 after acquiring an additional 7,160,065 shares during the period. Institutional investors own 70.36% of the company's stock.
Key Headlines Impacting Invivyd
Here are the key news stories impacting Invivyd this week:
- Negative Sentiment: Jill Andersen sold 34,939 shares on Feb. 18 at an average price of $1.58 (≈$55.2k); her holdings fell ~16.1% to 181,736 shares. SEC Filing
- Negative Sentiment: Jill Andersen sold 32,771 shares on Feb. 17 at $1.54 (≈$50.5k); that trade reduced her position by ~13.1%. SEC Filing
- Negative Sentiment: Timothy Edward Lee sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake declined ~15.1% to 117,717 shares. SEC Filing
- Negative Sentiment: Timothy Edward Lee sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his ownership fell ~12.4%. SEC Filing
- Negative Sentiment: William E. Duke (CFO) sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake dropped ~16.3% to 107,717 shares. SEC Filing
- Negative Sentiment: William E. Duke sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his position fell ~13.3%. SEC Filing
- Negative Sentiment: Julie Green sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); her holdings declined ~16.3% to 107,717 shares. SEC Filing
- Negative Sentiment: Julie Green sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); that trade lowered her stake ~13.3%. SEC Filing
- Negative Sentiment: Robert D. Allen III sold 19,392 shares on Feb. 18 at $1.58 (≈$30.6k); his holdings fell ~14.5% to 114,487 shares. SEC Filing
- Negative Sentiment: Robert D. Allen III sold 18,189 shares on Feb. 17 at $1.54 (≈$28.0k); his position declined ~12.0%. SEC Filing
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
